Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001709.5(BDNF):c.233G>A(p.Arg78Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000682 in 1,613,998 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
BDNF (HGNC:1033): (brain derived neurotrophic factor) This gene encodes a member of the nerve growth factor family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protein. Binding of this protein to its cognate receptor promotes neuronal survival in the adult brain. Expression of this gene is reduced in Alzheimer's, Parkinson's, and Huntington's disease patients. This gene may play a role in the regulation of the stress response and in the biology of mood disorders. [provided by RefSeq, Nov 2015]
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The c.233G>A (p.R78Q) alteration is located in exon 1 (coding exon 1) of the BDNF gene. This alteration results from a G to A substitution at nucleotide position 233, causing the arginine (R) at amino acid position 78 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
BDNF-related disorder Uncertain:1
Mar 21, 2024
PreventionGenetics, part of Exact Sciences
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing
The BDNF c.479G>A variant is predicted to result in the amino acid substitution p.Arg160Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);.;Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);.;Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);Gain of methylation at K76 (P = 0.0544);.;